Clinical Trials Browser

INDUSTRY × Neoplasm, Residual × N,N-dicyclohexyl-isoborneol-10-sulfonamide × Clear all

NCT00560794 2015-01-26

Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)

Phase 2 Completed

21 enrolled 19 charts

LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma